A drug to treat advanced prostate cancer should be given to patients on the NHS, a health watchdog has said.
Abirateron, marketed as Zytiga, can extend the lives of late-stage cancer sufferers by more than three months.
The National Institute for Health and Clinical Excellence (Nice) revised its recommendations after fresh information from manufacturer Janssen, and the new draft guidance was welcomed by experts.
More top news
A man became so frustrated with noise from a nearby building site that he shot a builder with an air rifle, police say.
A backbench revolt over proposals to ease purdah restrictions on the EU referendum has led to a government climb down.
It's been a colder start to the day, especially in rural areas of Britain.